On February 15, 2007, the board of SCN resolved to carry out a NOK 40 million directed issue of shares in cooperation with Norwegian Terra Securities ASA.

In preparation for a planned quotation on the Oslo Stock Exchange during spring 2007, the board of Scandinavian Clinical Nutrition i Sverige AB (publ) resolved on February 15 to carry out an issue of shares directed to Norwegian investors. The issue was carried out in cooperation with the company’s Norwegian financial partner Terra Securities ASA, and was fully subscribed for after the closing of the stock market yesterday.

There is great interest for companies like SCN on the Norwegian market. The company now faces a number of challenges, e.g. possible acquisitions, negotiations concerning licenses for new substances, and development of the company’s existing markets. The process leading to the current situation has been faster than expected, and a capital increase of NOK 40 million strengthens the company’s freedom of action.

More information:

Ulf Söderberg, CEO,, +46 708 13 22 81

Business Strategy Manager Anders Struksnes,, +47 911 98 942

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Membraseven and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth both in Sweden and on the company’s export markets. The SCN share is listed for trade on NGM Nordic MTF since December 6, 2006.


Documents & Links